How to prescribe Breztri (budesonide, glycopyrrolate, and formoterol) inhaler with Q24 hours dosing?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 26, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Prescribing Breztri Inhaler

Breztri (budesonide, glycopyrrolate, and formoterol) should be prescribed as 2 inhalations once daily with a quantity of one inhaler to be dispensed. This triple therapy inhaler is designed for once-daily dosing in the management of COPD.

Prescription Format

When writing a prescription for Breztri inhaler, include the following elements:

  • Medication Name: Breztri Aerosphere (budesonide 160 mcg, glycopyrrolate 9 mcg, formoterol fumarate 4.8 mcg)
  • Sig (Instructions): Inhale 2 puffs by mouth once daily
  • Quantity: 1 inhaler (120 inhalations)
  • Refills: As appropriate for patient's condition (typically 1-3)

Administration Instructions

For optimal therapeutic benefit, provide these additional instructions to the patient:

  • Shake well before each use
  • Exhale fully before placing the mouthpiece between lips
  • Inhale deeply and slowly while pressing down on the canister
  • Hold breath for 5-10 seconds after inhalation
  • Wait approximately 30 seconds between the two inhalations
  • Rinse mouth with water after use to prevent oral candidiasis

Clinical Evidence

Breztri Aerosphere is a fixed-dose combination of an inhaled corticosteroid (budesonide), a long-acting muscarinic antagonist (glycopyrrolate), and a long-acting β2-agonist (formoterol) that has demonstrated efficacy in reducing COPD exacerbations 1. The ETHOS trial showed that this triple therapy significantly reduced the rate of moderate or severe COPD exacerbations compared to dual therapies 2.

Important Considerations

  • Patient Selection: Appropriate for patients with moderate-to-very-severe COPD who have had at least one exacerbation in the past year
  • Monitoring: Regular assessment of symptom control and lung function
  • Adverse Effects: Monitor for potential adverse effects including pneumonia (3.5-4.5% incidence), oral candidiasis, and bronchospasm 2
  • Contraindications: Not for relief of acute bronchospasm or asthma without concomitant use of a controller medication

Common Pitfalls to Avoid

  1. Incorrect Dosing Frequency: Unlike some inhalers that require twice-daily dosing, Breztri is administered once daily
  2. Inadequate Patient Education: Ensure patients understand this is a maintenance medication, not a rescue inhaler
  3. Poor Inhaler Technique: Demonstrate proper technique and have the patient demonstrate it back
  4. Missing Mouth Rinsing: Emphasize the importance of rinsing the mouth after use to prevent oral fungal infections

Following these guidelines will help ensure appropriate prescribing of Breztri inhaler for patients with COPD requiring triple therapy.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.